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Abstract 
Total nutrient admixture (TNA) is a complete parenteral nutrition (PN) formulation composed of 
all macronutrients, including dextrose, amino acids, and intravenous fat emulsions (IVFE), in 
one bag. The TNA may be safely administered to the patient, with all components aseptically 
compounded and minimal administration manipulation required, lending itself to decreases in 
risks of catheter contamination and patient infections. The TNA is compatible and stable at 
recommended concentrations, and since the IVFE is in the TNA, it is infused at slower rates, 
allowing for better fat clearance. The TNA offers convenience of administration and a potential 
cost savings to the healthcare institution both directly and indirectly. Unfortunately, the TNA is 
not without concerns. At low macronutrient concentrations (lower than recommended), the 
formulation is compromised. Greater divalent and monovalent cation amounts and increased 
concentrations of phosphate and calcium may destabilize the TNA or result in precipitation, 
respectively. With the addition of IVFE in the TNA, catheter occlusion is greater and larger pore 
size filters are necessary, resulting in less microbial elimination. Determining if the 
implementation of the TNA is appropriate for an institution requires a recognition of the 
advantages and disadvantages of the TNA as well as an understanding of the institution’s patient 
population and their nutrition requirements. 
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Total nutrient admixture (TNA), sometimes referred to as 3-in-1, is the combination of all 
macronutrients (dextrose, amino acids, and intravenous fat emulsion [IVFE]) with electrolytes, 
vitamins, minerals, trace elements, and sterile water for injection in 1 intravenous (IV) solution. It 
is administered to patients when oral and/or enteral nutrition is contraindicated or inadequate and 
may be used for short-term periods to a lifetime of therapy. Likewise, 2-in-1 parenteral nutrition 
(PN) formulations may be used to meet patients’ nutrition requirements. Two-in-1 PN 
formulations are the combination of dextrose and amino acids along with electrolytes, vitamins, 
minerals, trace elements, and sterile water for injection, with IVFE infused separately as a source 
of calories and for the prevention of essential fatty acid deficiency. Which of the 2 therapies is 
superior has been debated, with the use of TNA considered conventionally acceptable and 
preferred in most institutional and home settings, but careful consideration must be given when 
choosing which therapy is best for one’s institution.1 Decisions should be made, giving thoughtful 
deliberation to patient safety, formulation compatibility with respect to patient populations, 
individual and institution convenience, and cost. An appreciation for each aspect of the process is 
necessary with patient safety and compatibility being imperative. Table 1 addresses each aspect of 
consideration for determining if the TNA is appropriate for implementation in healthcare 
institutions with further rationalization of each consideration explained in greater detail below. 
 
Safety 
When considering TNA and patient safety, microbial contamination and, ultimately, patients’ 
infectious complications are paramount. The compounding of both PN formulations and the 
potential of the formulation serving as a bacterial growth medium, as well as the administration of 
the PN, are all considered potential sources for microbial contamination resulting in patient 
infections. With the compounding of TNA, all components are aseptically prepared by the 
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pharmacy following the United States Pharmacopeia and National Formulary General Chapter 
<797> required for all healthcare institutions.2 Therefore, the TNA compounded in the pharmacy 
is considered a sterile formulation. Since the aseptic technique occurs with the compounding of 2-
in-1 PN formulations, the question of contamination and bacterial growth becomes the following: 
(1) Is there a difference between the 2 PN formulations as a growth medium, and (2) does the 
administration of the TNA vs 2-in-1 plus IVFE increase the risk of bacterial contamination and 
patients’ infections? 
In vitro studies have shown IVFE to serve as a growth medium for microorganisms, including 
Staphylococcus aureus and Candida albicans; however, 2-in-1 formulations did not foster growth 
of these microorganisms.3,4 In addition, the microorganisms grew only minimally to none when 
studied in TNA formulations.4 To determine if there is an observed difference between the 2 PN 
formulations and the risk for bacterial growth when administered to patients, Vasilakis and 
Apelgren5 cultured both 2-in-1 PN and IVFE given separately, as well as TNA. Two hundred PN 
fluid cultures were obtained from the distal most connection before the PN formulation was 
changed every 24 hours. Of the cultures obtained, 116 (83%) were negative, and with respect to 
the positive cultures, no significant differences were observed in the distribution between the TNA 
system (n = 19; 17% of 112) and the 2-in-1 PN and IVFE system (n = 15; 17% of 88). The 
investigators concluded that the TNA system did not increase the risk for contamination compared 
with the 2-in-1 PN system.5 
To determine if TNA administration influenced the rate of infection in clinical practice, 
investigators conducted a prospective randomized trial.6 Patients received either TNA or IVFE 
separately administered with the PN (L/PN). Ninety-six well-matched patients were evaluated. 
The incidence of infection was 12.6 and 10.3 per 1000 days of PN in the TNA group and L/PN 
group, respectively (P = .89). Microorganisms responsible for infection and the types of infections 
that developed were similar in both groups, leading the investigators to conclude that TNA 
administration does not influence the rate of infection in patients receiving PN.6 Since the IVFE 
does not need to be infused separately, there is arguably less risk for manipulation of the system 
and potentially a decrease in catheter contamination. However, concerning the adult population, 
this is theoretical as associations with the administration of IVFE and coagulase-negative 
staphylococcal bacteremia have been reported only in neonatal populations.7 With the research 
available, the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) PN Safety 
Guidelines suggest “there is no clinical difference in infectious complications between the two PN 
delivery systems.”8 
Another consideration with patient safety, which may be advantageous for administration of TNA, 
includes the slower infusion of IVFE. TNA may be infused for 24 hours, but because of the 
potential for IVFE to support microbial growth, the Centers for Disease Control and Prevention 
has recommended a maximal infusion time of 12 hours (eg, IVFE, propofol).9 IVFE for PN 
compounding currently used in the United States is composed of long-chain triglycerides from 
soybean oil–egg yolk phospholipid. When IVFE is rapidly infused at rates >1 kcal/kg/h (>0.11 
g/kg/h), the reticuloendothelial system (RES) and pulmonary, hepatic, and platelet function may 
be impaired.10 A 20% IVFE solution administered as a 10-hour infusion for 3 days was shown to 
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decrease the RES function by as much as 40%.11 No RES impairment was reported when IVFE 
was administered as 43% of nonprotein calories as a TNA. The administration of a continuous 
IVFE infusion appears to allow adequate lipid metabolism without adversely affecting the RES 
function.12 IVFE may depress the immune system, but the significance of these findings and their 
effect on patient outcome require further study.13 
Stability/Compatibility 
Total nutrient admixtures compounded with final concentrations of amino acid ≥4%, 
monohydrated dextrose ≥10%, and IVFE ≥2% are more likely to remain stable for up to 30 hours 
at room temperature (25°C) or for 9 days refrigerated (5°C) followed by 24 hours at room 
temperature according to the A.S.P.E.N. PN Safety Guidelines. These recommendations serve 
merely as a guide, and specific stability data on an individual TNA formulation should be 
sought.8,14 The stability of IVFE in the TNA is influenced by many factors, including pH, 
temperature, lipid globule, light exposure, container size, and storage conditions, and significant 
alterations may result in lipid globule coalescence (“cracking”) and precipitant formulation.13 
IVFE is generally most stable at its manufactured pH ~8. While amino acids are generally 
considered safe to combine with IVFE, dextrose in solution is acidic and can significantly decrease 
the pH of IVFE and consequently reduce surface potential and stability.15 In addition to the IVFE 
instability risk, a greater incidence of medication incompatibility with the IVFE is recognized. 
Generally, the addition of medications to the PN solution should be limited or none. If medications 
are added to the TNA or y-sited (preferred), compatibility and solubility charts should be consulted 
prior to infusion. 
Consideration of the institution’s patient population and whether the required macronutrient 
concentrations are appropriate to meet the needs of the patients is essential if the use of TNA is to 
be incorporated. If lower concentrations are warranted, 2-in-1 PN needs to be considered; however, 
similarly to the TNA, solution stability must be determined. 
Electrolytes and their concentration must also be considered when determining the appropriateness 
of TNA use. Trivalent (iron) > divalent (calcium, magnesium) > monovalent (sodium, potassium) 
cations may all cause a decrease in the surface potential of the lipid droplets, resulting in 
aggregation and coalescence.14 The concentration of electrolytes that will cause aggregation in a 
TNA with a given surface potential is called the critical aggregation number (CAN) and is 
calculated using the summed concentrations of mono-, di-, and trivalent cations.14 The CAN is 
influenced by factors such as the pH, amino acid concentration, and type of amino acid but can 
provide a guideline for predicting possible states of aggregation; however, no definitive studies 
exist for using the CAN with IVFEs commercially available in the United States. 
In the study by Driscoll et al,14 45 different TNA formulas were evaluated with final concentrations 
of monohydrated dextrose ranging 5%–20%, amino acids ranging 2.5%–7%, IVFE ranging 2%–
5%, monovalent cations ranging 0–150 mEq/L, divalent cations ranging 4–20 mEq/L, and trivalent 
cations (elemental iron/L) ranging 0–10 mg/L. Stability assessments, including particle size 
analysis, pH determination, and visual inspection, were performed. Monovalent, divalent, and 
trivalent cations clearly influenced the final admixture stability, with divalent concentrations 
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between 16 and 20 mEq/L requiring final concentrations of monohydrated dextrose >10% and 
amino acids >4% to prevent lipid destabilization.14 Therefore, if greater quantities of monovalent 
and divalent cations are required in an institution’s patient population, the use of TNA would not 
be feasible. This is supported by the A.S.P.E.N. PN Safety Recommendations, which state that 
“healthcare organizations should develop policies and/or protocols to allow modification of PN 
orders when potential incompatibilities may exist (eg, incompatibilities associated with calcium 
and phosphate salts, adjustment of IVFE dosing when it is not expected to be stable as a TNA, 
ordering IVFE separately or adjusting IVFE dosing such that the daily dose achieves minimum 
concentration for stability).”16 
Compatibility and the solubility of calcium gluconate and sodium or potassium phosphate are less 
in TNA formulations. Low pH concentrations (acidic) are more favorable in maintaining the 
solubility of calcium and phosphate. The added IVFE increases the pH of the bag, resulting in a 
greater likelihood of calcium-phosphate precipitate. For some adult patients receiving TNA, this 
is not a great concern since the intersection of final compounded calcium and phosphate 
concentrations in the clinical settings may fall below the typical solubility curve; however, this 
does have potential for complications in patients requiring greater concentrations of these 
electrolytes.17 
To assist in avoiding the hazards of precipitate, all PN formulations should be filtered according 
to the 1994 Food and Drug Administration safety alert.18 A disadvantage of the TNA system with 
the addition of IVFE is that it requires a larger pore size filter (1.2 µm) as opposed to the 2-in-1 
PN formulations, which use a 0.22-µm filter. The smaller pore size filter does eliminate a greater 
amount of particulate matter, including some bacteria (Staphylococcus epidermidis, Escherichia 
coli) than does the larger pore size; however, the 1.2-µm filter is adequate to remove precipitates 
(calcium-phosphate) and particulate matter as well as large organisms, including C albicans.13,17,19 
Increased filter occlusion rate and shortened catheter life span have been reported in home patients 
receiving TNA.20,21 The additional inclusion of IVFE associated with increased coalescence and 
precipitant formulation may be attributed to the reported incidences. And while often reported in 
pediatrics, increased filter occlusion has been observed in adult patients receiving TNA.21 Fibrin 
occlusions can be resolved by locking the catheter with recombinant tissue plasminogen activator, 
while IVFE occlusions can be minimized by flushing the central venous catheter with saline before 
and after TNA infusion and treated, once developed, using a 70% ethanol line lock if compatible 
with the IV catheter.22,23 
Convenience 
The convenience of TNA is an advantage to the healthcare providers and the patient. Pharmacy 
personnel are proficient and skilled at using an automated compounding device. The addition of 
IVFE into the PN formulation can be efficiently performed by pharmacy personnel and requires 
minimal additional time, especially if using an automatic compound device. Subsequently, less 
nursing time is required as an additional piggyback of IVFE is not required; in addition, and not 
surprisingly, the TNA system is preferred by nursing personnel.19,24 With respect to patients, the 
easier administration associated with TNA is advantageous for the patients and/or caregivers who 
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are required to administer the formulation. With the ease of only one container to administer, the 
success of delivery is greater, and potentially, patient compliance is better. 
Cost 
TNA has been associated with decreased cost.25,26 Decreased cost associated with TNA is 
attributed to a decrease in administration materials and nursing time. IV tubing, infusion pumps, 
and related supplies associated with the infusion of the IVFE piggyback are saved when TNA is 
implemented. Nursing time has been reported to decrease by nearly half (2.2 vs 4.3 hours) with 
the TNA system compared with the 2-in-1 plus a separate IVFE infusion.25 
Multichamber Bags 
Multichamber bags (MCBs) are industry-compounded, commercially available, ready-to-use PN 
bags. In the United States, MCBs are available both with and without IVFE. Multichamber bags 
may be used for standard PN in adults but do not eliminate the need for individualized PN therapy. 
Patient specific nutrient requirements must be met and MCBs are appropriate only if this is 
possible. Early research has been conducted demonstrating a decrease in infectious complications 
and lower cost; however, greater investigation is warranted.27,28 As well, whether there will be an 
advantage between MCBs with and without IVFE will need to be studied. 
Conclusion 
The TNA formulations, following A.S.P.E.N. PN Safe Practice Guidelines and Recommendations 
with respect to ordering, reviewing, compounding, labeling, and administering, are safe and 
appropriate in many institutional settings. As well, both patients and healthcare providers find the 
use of the TNA to be advantageous with respect to conveniences of the therapy, and potentially, 
there is an associated cost saving directly with less equipment and supplies used and indirectly 
with less administrative time involved. However, TNAs are not appropriate for all patients and 
institutions. Specific patients’ nutrition requirements, especially those requiring larger monovalent 
and divalent cations, as well as calcium and phosphate concentrations, may require the use of 2-
in-1 PN formulations. Careful consideration with respect to the institution’s patient population in 
determining the best PN formulation is essential. 
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